Jyong Biotech Ltd. Ordinary Shares (MENS) is a publicly traded Healthcare sector company. As of May 21, 2026, MENS trades at $2.17 with a market cap of $144.76M and a P/E ratio of 0.00. MENS moved -4.13% today. Year to date, MENS is -38.00%; over the trailing twelve months it is flat. Its 52-week range spans $1.43 to $67.00. Rallies surfaces MENS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Jyong Biotech’s Botreso® Completes Four Phase III Trials; PCP Shows Cancer Prevention Trends: Jyong Biotech’s Botreso® completed four Phase III trials in the US and Taiwan, and its PCP drug finished a two-year Phase II study with 702 subjects across 20 hospitals, showing no drug-related adverse events. Clinical data highlight metabolic improvements—reduced triglycerides, lower LDL, higher HDL—and PCP trends toward prostate cancer prevention.
| Metric | Value |
|---|---|
| Price | $2.17 |
| Market Cap | $144.76M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $67.00 |
| 52-Week Low | $1.43 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
MENS analyst coverage data. Average price target: $0.00.